Bioavailability of Cariban® Capsules: A Modified-Release Fixed-Dose Combination of Doxylamine and Pyridoxine to Relieve Nausea and Vomiting During Pregnancy

• Published in: Drugs in R&D Vol. 23; no. 2; pp. 185 - 195
• Main Authors: Saz-Leal, Paula, Zamorano-Domínguez, Laura, Frías, Jesús, Guerra, Pedro, Saura-Valls, Marc, Roca-Juanes, Ramón, Nebot-Troyano, Joaquín, García-Aguilar, Eva, Vilchez, Tatiana, Urso, Katia
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.06.2023; Adis, Springer Healthcare
• Subjects: Adult; Antiemetics - pharmacokinetics; Antiemetics - therapeutic use; Biological Availability; Capsules; Delayed-Action Preparations; Doxylamine - pharmacokinetics; Drug Combinations; Female; Humans; Internal Medicine; Medicine; Medicine & Public Health; Nausea; Original; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy; Pregnancy; Pregnancy Complications - drug therapy; Pyridoxine - pharmacokinetics; Pyridoxine - therapeutic use; Vomiting - drug therapy
• ISSN: 1174-5886; 1179-6901
• DOI: 10.1007/s40268-023-00425-7

Background Nausea and vomiting is a very prevalent condition during pregnancy. Combination of doxylamine and pyridoxine is placed as first-line pharmacological option for its treatment in most clinical guidelines. Among different release forms available, Cariban ® is a fixed-dose combination of doxylamine/pyridoxine 10/10 mg, formulated as modified-release capsules. Objectives In the present study, we aimed to characterize the bioavailability performance of Cariban ® in vitro and in vivo. Methods An in vitro dissolution test was performed to evaluate the release profile of Cariban ® , together with immediate- and delayed-release formulations available on the market. A single-center, single-dose, open-label bioavailability study following Cariban ® administration in 12 healthy adult female patients was carried out to explore the drug behavior in vivo (protocol NBR-002-13; EUDRA-CT 2013-005422-35). These data were additionally used to perform a computational pharmacokinetic simulation of the posology approved for this drug. Results Cariban ® capsules demonstrate a prolonged-release performance, with an early, gradual, and progressive release of both actives until reaching a complete dissolution after 4–5 h in solution. The pharmacokinetic features of these capsules show that doxylamine and pyridoxine metabolites are early absorbed, being all detectable in plasma within 1 h following oral administration. Computational pharmacokinetic simulation predicts that different posology provides distinct profiles of metabolites in plasma, with 1–1–2 (morning–midafternoon–night) being the one that concentrates higher plasma levels but lower dose dumping for 24 h. Conclusion Cariban ® behaves as a prolonged-release formulation, which correlates with rapid absorption and arising of the actives in the plasma, but also long-lasting and sustained bioavailability, especially when administered following the complete posology. These results would underlie its demonstrated efficacy to relieve nausea and vomiting of pregnancy (NVP) under clinical settings.